FindTrial
Sign In

Treatment of HIV/AIDS patients with Glutamine Dipeptide

Impact of Glutamine Dipeptide Supplementation in HIV/AIDS patients treated with antiretroviral therapy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-843tnq
Enrollment
Unknown
Registered
2015-09-21
Start date
2015-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease caused by human immunodeficiency virus

Interventions

Experimental groups: 1) 50 HIV-positive patients with stable viral load within 6 months and regular use of antiviral therapy will be treated with dipeptide glutamine (20g) dissolved in water and inges
Dietary supplement
SP6.051.227

Sponsors

UEM-Universidade Estadual de Maringá
Lead Sponsor
UEM-Universidade Estadual de Maringá
Collaborator

Eligibility

Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: HIV positive; both genders; between 18 and 60 years; regular use of antiretroviral therapy; good adherence to therapy; HIV viral load stable in the last 6 months

Exclusion criteria

Exclusion criteria: pregnant women; psychiatric patients; more than 60 years old; chronic kidney disease; swallowing difficulty.

Design outcomes

Primary

MeasureTime frame
The improvement of the patient is assessed by reduction in immunosuppression process and viral load by conducting laboratory measurements of cytokines and the immune status indicator cells, and HIV load.—

Secondary

MeasureTime frame
Secondary outcomes are not expected—

Countries

Brazil

Contacts

Public ContactMaria Raffaini Cóvas Pereira da Silva

Universidade Estadual de Maringá

marcpsilva@uem.br+55 44 30115168

Outcome results

None listed

Source: REBEC (via WHO ICTRP)